|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:activeIngredient
|
gptkb:denosumab
|
|
gptkbp:approvalYear
|
2010
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:associatedWith
|
gptkb:Xgeva
|
|
gptkbp:ATCCode
|
gptkb:M05BX04
|
|
gptkbp:brand
|
gptkb:Prolia
|
|
gptkbp:chemicalFormula
|
gptkb:C6400H9908N1720O2016S44
|
|
gptkbp:contraindication
|
hypocalcemia
|
|
gptkbp:drugClass
|
gptkb:monoclonal_antibody
|
|
gptkbp:form
|
solution for injection
|
|
gptkbp:frequency
|
every 6 months
|
|
gptkbp:genericName
|
gptkb:denosumab
|
|
gptkbp:halfLife
|
25 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Prolia
|
|
gptkbp:immunogenicity
|
low
|
|
gptkbp:indication
|
bone loss due to hormone ablation in cancer
men at increased risk of fractures
postmenopausal women with osteoporosis
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Amgen
|
|
gptkbp:marketedIn
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
RANKL inhibitor
|
|
gptkbp:molecularWeight
|
147 kDa
|
|
gptkbp:monitoredParameter
|
renal function
serum calcium
signs of infection
|
|
gptkbp:patent
|
gptkb:Amgen
|
|
gptkbp:pharmacokinetics
|
linear
|
|
gptkbp:pregnancyCategory
|
Category D
not recommended
Category X
|
|
gptkbp:prescriptionRequired
|
https://www.prolia.com/
|
|
gptkbp:prescriptionStatus
|
Rx only
|
|
gptkbp:reimbursementStatus
|
covered by Medicare Part B (US)
|
|
gptkbp:riskFactor
|
skin infections
hypersensitivity reactions
osteonecrosis of the jaw
atypical femoral fracture
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:sideEffect
|
infections
dermatitis
hypocalcemia
osteonecrosis of the jaw
|
|
gptkbp:storage
|
2-8°C
|
|
gptkbp:usedFor
|
gptkb:bone
bone loss
|
|
gptkbp:bfsParent
|
gptkb:Amgen
|
|
gptkbp:bfsLayer
|
6
|